{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:34:34Z","timestamp":1781620474757,"version":"3.54.5"},"reference-count":50,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.clml.2022.05.001","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T01:19:46Z","timestamp":1653095986000},"page":"e874-e883","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Impact of Lenalidomide Treatment on Overall Survival in Patients With Lower-Risk, Transfusion-Dependent Myelodysplastic Syndromes"],"prefix":"10.1016","volume":"22","author":[{"given":"Valeria","family":"Santini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristoteles","family":"Giagounidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5255-2777","authenticated-orcid":false,"given":"Christopher G.","family":"Pelligra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrado","family":"Franco-Villalobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Morison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CL","family":"Beach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.05.001_bib0001","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41408-018-0085-4","article-title":"Myelodysplastic syndromes current treatment algorithm 2018","volume":"8","author":"Steensma","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2022.05.001_bib0002","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ajh.21959","article-title":"Transfusion intensity, not the cumulative red blood cell transfusion burden, determines the prognosis of patients with myelodysplastic syndrome on chronic transfusion support","volume":"86","author":"Pereira","year":"2011","journal-title":"Am J Hematol"},{"issue":"3)","key":"10.1016\/j.clml.2022.05.001_bib0003","doi-asserted-by":"crossref","first-page":"iii57","DOI":"10.1093\/annonc\/mdu180","article-title":"Myelodysplastic syndromes: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Fenaux","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2022.05.001_bib0004","doi-asserted-by":"crossref","first-page":"60","DOI":"10.6004\/jnccn.2017.0007","article-title":"Myelodysplastic syndromes, Version 2.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Greenberg","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2022.05.001_bib0005","unstructured":"National Cancer Care Network (NCCN). Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Myelodysplastic syndromes; Version3. 2021. Available at: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1446. Accessed: September 16, 2021."},{"key":"10.1016\/j.clml.2022.05.001_bib0006","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.05.001_bib0007","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1200\/JCO.2016.71.3271","article-title":"Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents","volume":"35","author":"Park","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.05.001_bib0008","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3026(17)30012-1","article-title":"Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial","volume":"4","author":"Oliva","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2022.05.001_bib0009","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/cncr.30383","article-title":"Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents","volume":"123","author":"Jabbour","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.05.001_bib0010","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood.V95.4.1175.004k51_1175_1179","article-title":"Effect of recombinant human erythropoietin combined with granulocyte\/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM\/EPO MDS Study Group","volume":"95","author":"Thompson","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.05.001_bib0011","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMp048266","article-title":"Myelodysplastic syndromes \u2014 coping with ineffective hematopoiesis","volume":"352","author":"Cazzola","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.05.001_bib0012","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2011.044602","article-title":"Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based prognostic Scoring System (WPSS)","volume":"96","author":"Malcovati","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.05.001_bib0013","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1200\/JCO.2005.01.7038","article-title":"Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making","volume":"23","author":"Malcovati","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.05.001_bib0014","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s12185-017-2367-1","article-title":"Iron overload in myelodysplastic syndromes (MDS)","volume":"107","author":"Gattermann","year":"2018","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2022.05.001_bib0015","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1182\/blood.V118.21.2775.2775","article-title":"Transfusion-dependency is the most important prognostic factor for survival in 1000 newly diagnosed MDS patients with low- and intermediate-1 risk MDS in the European LeukemiaNet MDS registry","volume":"118","author":"de Swart","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.05.001_bib0016","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3324\/haematol.2017.171884","article-title":"Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes","volume":"103","author":"de Swart","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.05.001_bib0017","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","article-title":"A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-\/intermediate-1-risk myelodysplastic syndromes with del5q","volume":"118","author":"Fenaux","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.05.001_bib0018","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/ajh.23303","article-title":"Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes","volume":"87","author":"Komrokji","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.05.001_bib0019","doi-asserted-by":"crossref","first-page":"292","DOI":"10.5455\/msm.2014.26.292-296","article-title":"Influence of prognostic factors on overall survival in myelodysplastic syndromes","volume":"26","author":"Sotirova","year":"2014","journal-title":"Mater Sociomed"},{"key":"10.1016\/j.clml.2022.05.001_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179016","article-title":"Role of serum ferritin level on overall survival in patients with myelodysplastic syndromes: results of a meta-analysis of observational studies","volume":"12","author":"Pileggi","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2022.05.001_bib0021","doi-asserted-by":"crossref","first-page":"e17406","DOI":"10.1097\/MD.0000000000017406","article-title":"The impact of iron chelation therapy on patients with lower\/intermediate IPSS MDS and the prognostic role of elevated serum ferritin in patients with MDS and AML: a meta-analysis","volume":"98","author":"Yang","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clml.2022.05.001_bib0022","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3324\/haematol.2018.212332","article-title":"Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry","volume":"105","author":"Hoeks","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.05.001_bib0023","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/M19-0916","article-title":"Iron chelation in transfusion-dependent patients with low- to intermediate-1-risk myelodysplastic syndromes: a randomized trial","volume":"172","author":"Angelucci","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2022.05.001_bib0024","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1182\/blood-2018-10-844696","article-title":"Treatment of MDS","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.05.001_bib0025","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1182\/blood-2018-06-857102","article-title":"Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.05.001_bib0026","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1182\/blood.V122.21.1518.1518","article-title":"Transfusion dependency is associated with inferior survival even in very low and low risk IPSS-R patients","volume":"122","author":"Hiwase","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.05.001_bib0027","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.05.001_bib0028","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1182\/blood-2019-129464","article-title":"Intermittent transfusion independence is associated with improved overall survival in patients with transfusion dependent MDS","volume":"134","author":"Buckstein","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.05.001_bib0029","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000445163","article-title":"Association between transfusion status and overall survival in patients with myelodysplastic syndromes: a systematic literature review and meta-analysis","volume":"136","author":"Harnan","year":"2016","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2022.05.001_bib0030","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/annonc\/mdv488","article-title":"Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes","volume":"27","author":"Komrokji","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2022.05.001_bib0031","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/bloodadvances.2018020495","article-title":"Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes","volume":"2","author":"Itzykson","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.05.001_bib0032","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/bloodadvances.2018019414","article-title":"The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort","volume":"2","author":"Stahl","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.05.001_bib0033","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/ejh.13160","article-title":"Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study)","volume":"101","author":"Wehmeyer","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2022.05.001_bib0034","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.3324\/haematol.2017.183590","article-title":"Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low\/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study","volume":"104","author":"Messa","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.05.001_bib0035","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.7150\/jca.33175","article-title":"A meta-analysis of higher-risk myelodysplastic syndrome trials to evaluate the relationship between short-term endpoints and overall survival","volume":"10","author":"Kurumaddali","year":"2019","journal-title":"J Cancer"},{"key":"10.1016\/j.clml.2022.05.001_bib0036","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.05.001_bib0037","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1200\/JCO.2015.66.0118","article-title":"Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents","volume":"34","author":"Santini","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.05.001_bib0038","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/ejh.12380","article-title":"Outcomes in RBC transfusion-dependent patients with Low-\/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study","volume":"93","author":"Giagounidis","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2022.05.001_bib0039","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2013.305","article-title":"Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS","volume":"28","author":"List","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.05.001_bib0040","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.3109\/10428194.2013.778406","article-title":"Lenalidomide in international prognostic scoring system low and intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy","volume":"54","author":"Oliva","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.05.001_bib0041","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.523","article-title":"Early lenalidomide treatment for low and intermediate-1 international prognostic scoring system risk myelodysplastic syndromes with del(5q) before transfusion dependence","volume":"4","author":"Oliva","year":"2015","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2022.05.001_bib0042","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3109\/10428194.2013.820286","article-title":"Health care utilization and risk of infection and bleeding among patients with myelodysplastic syndromes with\/without transfusions, and with\/without active therapy","volume":"55","author":"Smith","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.05.001_bib0043","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1080\/10428194.2017.1312372","article-title":"Patterns of treatment and costs associated with transfusion burden in patients with myelodysplastic syndromes","volume":"58","author":"DeZern","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.05.001_bib0044","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1111\/j.1537-2995.2012.03626.x","article-title":"Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need","volume":"52","author":"Goldberg","year":"2012","journal-title":"Transfusion"},{"key":"10.1016\/j.clml.2022.05.001_bib0045","doi-asserted-by":"crossref","first-page":"PCN33","DOI":"10.1016\/j.jval.2011.02.891","article-title":"Cost savings associated with transfusion independence in patients with myelodysplastic syndrome with a 5q- deletion","volume":"14","author":"Bozkaya","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.clml.2022.05.001_bib0046","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1182\/blood.V128.22.4327.4327","article-title":"Elevated labile plasma iron levels (LPI) and increased oxidative stress are associated with red blood cell transfusions in patients with lower-risk myelodysplastic syndromes (MDS): from the European LeukemiaNet MDS Registry","volume":"128","author":"Hoeks","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.05.001_bib0047","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.bbmt.2015.11.820","article-title":"Transfusion history is the most significant predictor of iron overload after allogeneic stem cell transplantation","volume":"22","author":"Lindsay","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2022.05.001_bib0048","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-017-0491-2","article-title":"Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)","volume":"10","author":"Fenaux","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2022.05.001_bib0049","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165948","article-title":"Efficacy and safety of lenalidomide for treatment of low-\/intermediate-1-risk myelodysplastic syndromes with or without 5q deletion: a systematic review and meta-analysis","volume":"11","author":"Lian","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2022.05.001_bib0050","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/s41375-020-0961-3","article-title":"Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients","volume":"35","author":"Santini","year":"2021","journal-title":"Leukemia"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022001525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022001525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:40:07Z","timestamp":1761871207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022001525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2152265022001525"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.05.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Lenalidomide Treatment on Overall Survival in Patients With Lower-Risk, Transfusion-Dependent Myelodysplastic Syndromes","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}